Skip to content

Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial

January 16, 2022

From the Forbes website

In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.  

It is likely that private insurers will follow Medicare lead and refuse to pay for the drug. Manufacturer Biogen’s initial price for Aduhelm was $56,000-a-year for a typical patient. Faced with resistance from most physicians and little demand, Biogen cut the price in half to $28,000 in December. But even that price is far too steep for consumers to pay out-of-pocket.

Continue reading

From → Health & Safety

Comments are closed.